OVERVIEW

  • Understand the disease burden and pathophysiology for acute ischemic stroke (AIS), and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attack (TIA).
  • Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population
  • Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial

This content is developed exclusively by or on behalf of the industry sponsor through a third party and is not reviewed by Pri-Med. The content and opinions expressed are those of the sponsor or presenters and may not reflect the views of Pri-Med.